Lorglumide

From Wikipedia, the free encyclopedia
Lorglumide
Systematic (IUPAC) name
N2-(3,4-dichlorobenzoyl-N,N-dipentyl-α-glutamine
Clinical data
Legal status ?
Identifiers
CAS number 97964-56-2 YesY
ATC code None
PubChem CID 3960
IUPHAR ligand 891
UNII LAD1UQ73BE N
ChEMBL CHEMBL24938 N
Synonyms 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
Chemical data
Formula C22H32Cl2N2O4 
Mol. mass 459.406 g/mol
 N (what is this?)  (verify)

Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist,[1] with fairly high selectivity for the CCKA subtype.[2] It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.[3][4][5][6]

References

  1. ↑ Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. PMID 3440035
  2. ↑ González-Puga C, García-Navarro A, Escames G, León J, López-Cantarero M, Ros E, Acuña-Castroviejo D. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. Journal of Pineal Research. 2005 Oct;39(3):243-50. doi:10.1111/j.1600-079X.2005.00239.x PMID 16150104
  3. ↑ de Tullio P, Delarge J, Pirotte B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Current Medicinal Chemistry. 1999 Jun;6(6):433-55. PMID 10213792
  4. ↑ de Tullio P, Delarge J, Pirotte B. Therapeutic and chemical developments of cholecystokinin receptor ligands. Expert Opinion on Investigational Drugs. 2000 Jan;9(1):129-46. PMID 11060666
  5. ↑ Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Medical Research Reviews. 2003 Sep;23(5):559-605. PMID 12789687
  6. ↑ Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Current Opinion in Pharmacology. 2007 Dec;7(6):583-92. PMID 17997137


Drugs for
functional
bowel disorders
Tertiary
amino group
Quaternary
ammonium
compounds
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives

M: DIG

anat (t, g, p)/phys/devp/enzy

noco/cong/tumr, sysi/epon

proc, drug (A2A/2B/3/4/5/6/7/14/16), blte

H2 antagonists ("-tidine")
Prostaglandins (E)/analogues ("-prost-")
Proton-pump inhibitors ("-prazole")
Other

M: DIG

anat (t, g, p)/phys/devp/enzy

noco/cong/tumr, sysi/epon

proc, drug (A2A/2B/3/4/5/6/7/14/16), blte

Cholecystokinin
CRH
CRF1
  • Agonists: Corticotropin releasing hormone
Galanin
Ghrelin
GnRH
MCH
Melanocortin
Neuropeptide S
Neuropeptide Y
Neurotensin
Orexin
Oxytocin
Tachykinin
Vasopressin
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.